Seismic Therapeutic Appoints Julie Eastland to Board of Directors
Seismic Therapeutic, Inc., a leader in machine learning-based immunology, is excited to announce that Julie Eastland has joined its Board as an Independent Director. With over thirty years of rich experience in finance and strategy specifically within the clinical-stage biotechnology sector, Ms. Eastland brings invaluable expertise that aligns seamlessly with the company’s mission to deliver groundbreaking therapeutics to patients facing major challenges in oncology and immunology.
Julie's Background and Expertise
Jo Viney, PhD, the Co-founder, President, and CEO of Seismic Therapeutic, expressed his enthusiasm for Eastland's appointment. He said, "We are thrilled to welcome Julie to our Board of Directors. With her proven track record as an independent Director and executive in the biopharmaceutical industry, Julie offers deep insights across the continuum of company growth and drug development, stretching from discovery to commercialization." This statement underscores the vital role Eastland is expected to play in steering the company's strategic goals.
Effect on Drug Development and Business Expansion
Eastland's extensive experience in guiding companies toward effective organizational growth will be crucial for Seismic as it progresses its operations and moves its inaugural candidates into clinical pathways. She remarked, "Joining Seismic’s Board is a privilege as the company shifts significantly in how immunology therapies are discovered and developed, powered by machine learning." This illustrates her dedication to innovation within the field of immunology therapies.
Executive Roles in Biotechnology
Before this, Ms. Eastland served as the Chief Executive Officer and Board Director at Harpoon Therapeutics, a firm dedicated to developing T-cell engagers for cancer treatments. Her leadership there, from late 2021 until Harpoon's acquisition by a major global pharmaceutical entity, equipped her with invaluable insights into the biotech landscape. She has also held key positions as Chief Operating Officer and Chief Financial Officer at ReCode Therapeutics, solidifying her reputation in the biotechnology arena.
Her Role at Seismic Therapeutic
Alongside her executive responsibilities, Julie Eastland currently sits on the boards of Dynavax Technologies (DVAX) and Lantheus Holdings Inc (LNTH), illustrating her influence across numerous organizations. She's also involved with Veana Therapeutics, broadening her impact beyond a single firm. Her academic credentials include an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.
About Seismic Therapeutic
Seismic Therapeutic is at the forefront of transforming how immunology therapies are discovered and developed through its strategic application of machine learning. The company is focused on advancing a highly innovative pipeline that features both first-in-class and best-in-class biologics. Through its unique IMPACT platform, Seismic aims to enhance the regulation of adaptive immunity, targeting various autoimmune diseases that significantly impact patient populations.
Supported by a diverse group of life sciences investors, Seismic is strategically positioned within the Boston biotechnology ecosystem. The company is committed to delivering state-of-the-art therapies that have the potential to reshape the treatment landscape for conditions marked by substantial unmet medical needs.
Frequently Asked Questions
What is the role of Julie Eastland at Seismic Therapeutic?
Julie Eastland has been appointed as an Independent Director on the Board of Seismic Therapeutic, bringing over 30 years of experience in biotechnology and finance.
What qualifications does Julie Eastland hold?
Julie Eastland earned an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University, along with extensive leadership roles in various biotech companies.
What is the focus of Seismic Therapeutic's innovations?
Seismic Therapeutic is focused on leveraging machine learning to discover and develop new immunology therapies, particularly targeting autoimmune diseases.
Which companies has Julie Eastland previously worked with?
Julie Eastland has held significant leadership roles at Harpoon Therapeutics, ReCode Therapeutics, and Cascadian Therapeutics, among other biotechnology firms.
What is the IMPACT platform?
The IMPACT platform is Seismic Therapeutic’s distinctive approach designed to regulate dysregulated adaptive immunity effectively, addressing various autoimmune disorders.
